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reinterventions, and endoleaks after endovascular
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Objective: The Endovascular aneurysm repair Risk Assessment (ERA) model predicts survival (early death, 3-year survival,
and 5-year survival), reinterventions, and endoleaks after elective endovascular aneurysm repair. We externally validated
the ERA model in our cohort of patients.
Methods: This was a retrospective validation study of 433 consecutive patients with an asymptomatic abdominal aortic
aneurysm treated with endovascular aneurysm repair in three hospitals (Amsterdam, The Netherlands) between 1997 and
2010. The area under the receiver operating characteristic curve was used as measure of accuracy (>0.70 was considered as
sufﬁciently accurate).
Results: The early death rate was 1% (3 of 433; 95% conﬁdence interval [CI], 0%-2%), the 5-year survival rate was 65%
(95% CI, 61%-70%), the 5-year reintervention rate was 18% (95% CI, 14-78%), and the 5-year rate of type I, II, or III
endoleak was 25% (95% CI, 20%-29%). The areas under the curve varied between 0.64 and 0.66 for predictions of survival
and between 0.47 and 0.61 for reinterventions and endoleaks.
Conclusions: The predictions of survival, reinterventions, and endoleaks made by the ERA model were not sufﬁciently
accurate to be used in our clinical practice. (J Vasc Surg 2014;59:1555-61.)During the past two decades, the treatment of abdom- treatments will beneﬁt the patient most: OR, EVAR, or
inal aortic aneurysms (AAAs) has been subject to change.
Conventional open repair (OR) has been partially
substituted by endovascular aneurysm repair (EVAR).
Recent clinical trials have shown that 30-day mortality is
lower after EVAR than after OR.1-3 However, the inci-
dence of reinterventions and endograft-related complica-
tions is higher after EVAR than after OR. A challenge in
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assessing individual outcomes after intervention and can
support clinical decision making for elective aortic surgery.
A promising prediction model is the EVAR Risk
Assessment (ERA) model. The ERA model includes only
eight preoperative variables (Table I).4,5 The ERA model
has been designed to predict survival-related outcomes
(30-day death, 3-year and 5-year survival, and aneurysm-
related death), the need for reintervention, type I and
type II endoleaks, and other complications, including tech-
nical success, graft complications, migration, and conver-
sion. In aortic surgery, many models have been
developed predicting the 30-day or in-hospital death rate
and reinterventions or complications separately. Until
now, the ERA model is the only one that predicts all of
these outcomes together. These combined predictions are
a major advantage that could potentially support decision
making. The model was validated on three occasions: inter-
nally, using bootstrapping in the original Australian cohort
and externally in the United Kingdom6 and in Australia.7
The predictions of survival (30-day, 3-year, and 5-year)
and type I endoleak (30-day and midterm) were sufﬁciently
accurate. The ERA model is freely available at http://
health.adelaide.edu.au/surgery/evar/predictive.html or
for a small fee as an iPhone application.
The primary objective of the present study was a third
external validation of the ERA model using a Dutch
cohort of patients. A secondary objective was the identiﬁ-
cation of preoperative variables that might improve the
ERA model.1555
Table I. Baseline characteristics and the preoperative
variables included in the EVAR Risk Assessment (ERA)
model
Baseline characteristics Value
Variable
included
in the ERA
model?
Sex Yes
Male 89 (386)
Female 11 (47)
Age, years 73.9 6 7.4 Yes
BMI, kg/m2 26.1 6 3.8 No
Current smoking 43 (155/359) No
Comorbidity
Cardiac (SVS/ISCS score $1) 59 (246/420) No
Cerebrovascular (SVS/ISCS
score $1)
13 (57/429) No
Previous history of
malignancy
23 (101/433) No
ASA score $3 60 (261/433) Yes
GAS 80 6 10 No
Anemia 26 (111/424) No
Serum creatinine, mmol/L 88 (75-105) Yes
Max aneurysm diameter, mm 62 6 11 Yes
Infrarenal neck, mm
Length 33 6 13 Yes
Diameter 24 6 3 Yes
Aneurysm angulation $45 19 (67/349) Yes
Late generation endograft 55 (220/399) No
Adjunctive procedure 20 (86/433) No
ASA, American Society of Anesthesiologists; BMI, body mass index; EVAR,
endovascular aneurysm repair; GAS, Glasgow Aneurysm Score; ISCS, In-
ternational Society for Cardiovascular Surgery; IQR, interquartile range;
SD, standard deviation; SVS, Society for Vascular Surgery.
Continuous data are presented as mean 6 standard deviation or median
(IQR) and categorical data as percentage (number).
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We conducted a retrospective cohort study at the Aca-
demic Medical Centre (tertiary university hospital), at the
Onze Lieve Vrouwe Gasthuis (teaching hospital), and at
the VU University Medical Centre (tertiary university hos-
pital) in Amsterdam, The Netherlands. Included were all
consecutive patients with EVAR for an asymptomatic aneu-
rysm of the infrarenal abdominal aorta between January 1,
1997, and January 1, 2010. Patients with an inﬂammatory
aneurysm were excluded.
All patients had routine follow-up, according to local
practice, with yearly computed tomography angiography
(CTA) or duplex ultrasound imaging combined with plain
abdominal X-ray imaging. Patient follow-up was assessed
up to July 1, 2012. Primary end points were death, reinter-
ventions, and type I, II, and III endoleaks. The outcomes
of 30-day death, 3-year survival, and 5-year survival will be
referred to as the “survival-related outcomes.” The present
study focused on the validation of the predictions of these
survival-related outcomes, reinterventions, and endoleaks
by the ERA model. Because of a very low number of au-
topsies, cause of death was considered to be unreliable,
and we did not validate the predictions of aneurysm-
related death. Because of the retrospective design, we didnot validate the predictions of technical success, graft com-
plications, migration, and conversion.
Data collection. Data were collected from medical re-
cords, discharge documents, preoperative anesthesia assess-
ment records, and operative reports. Data were entered by
the ﬁrst author using Ofﬁce Access 2003 (Microsoft Corp,
Redmond, Wash) and included ﬁeld limits and multivariate
checks. Patients were identiﬁed from a prospective registry
(Academic Medical Centre) and from the ﬁnancial coding
administration of interventions (Onze Lieve Vrouwe Gas-
thuis and VU University Medical Centre).
Deﬁnitions of preoperative variables8 and postoperative
outcomes9 were in accordance with the reporting standards
of the Society for Vascular Surgery and the International
Society forCardiovascular Surgery (SVS/ISCS) and the article
ﬁrst describing the ERA model.4 Early death was deﬁned as
the 30-day death rate. Reinterventions and endoleaks were
assessed twice postoperatively: as deﬁned by the ERA
model, “initial” encompassed the ﬁrst 30days, and “midterm”
referred to the period between 30 days and 5 years.
As in the ERA model, conversions to OR were sepa-
rately analyzed from reinterventions, and type III endo-
leaks were included as type I in the statistical analysis.
Anemia was deﬁned as hemoglobin <134 g/L
(<8.4 mmol/L) in men and <117 g/L (<7.3 mmol/L)
in women. A previous history of malignancy included all
types of cancer except nonmelanoma dermal carcinoma.
Endografts were dichotomized into early generation
and late generation. Early generation encompassed the
endografts formerly used in daily practice, which were the
Lifepath (Edwards Lifesciences, Irvine, Calif) in 6, the
Ancure (Endovascular Technologies, Menlo Park, Calif)
in 8, the Talent (Medtronic, Minneapolis, Minn) in 100,
the AneuRx (Medtronic) in 45, and an investigational Cor-
dis endograft (Johnson & Johnson, New Brunswick, NJ) in
4. The late generation encompassed endografts currently
used in daily practice, which are the Zenith (Cook Medical,
Bloomington, Ind) in 196, the Endurant (Medtronic) in
24, and the Gore Excluder (W. L. Gore & Associates, Flag-
staff, Ariz) in 16.
Aneurysm characteristics were measured in the sagittal,
coronal, and axial planes of the preoperative CTA. Date of
death was obtained from medical records and general prac-
titioner registers.
Statistical analysis. The statistical analysis was done
using SPSS 19.0 software (IBM Inc, Armonk, NY) and R
(The R Foundation for Statistical Computing, Boston,
Mass). Continuous data are described by the mean with
corresponding standard deviation for data normally distrib-
uted, and by the median with corresponding interquartile
range (IQR) for data with a skewed distribution. The 5-
year survival, reintervention, and endoleak rates were esti-
mated by Kaplan-Meier survival analyses and compared
with use of the log-rank test. Also reported are the actual
outcome rates in patients treated before July 1, 2007.
The statistical analysis comprised three steps. First, the
accuracy of the ERA model was assessed for discrimination
and calibration. Discrimination is the ability of a model to
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between dying and surviving patients. Discrimination was
assessed using the area under the receiver operating charac-
teristic curve (AUC), speciﬁcally using the Harrell C statis-
tic,10 which takes into account patients who are censored
before the end point. An AUC of >0.70 is generally
considered sufﬁciently accurate. Calibration refers to the
agreement between predicted and observed outcomes
and was assessed by plotting the predicted outcomes in
quintiles with the corresponding observed outcomes. Cali-
bration was assessed for 3-year and 5-year survival and
included only patients who had the intervention before
July 2009 and July 2007 to ensure sufﬁcient follow-up
time.
Second, preoperative variables that might improve the
predictions of survival-related outcomes of the ERA model
were identiﬁed using a Cox proportional hazards model.
First, a univariable survival analysis was done including vari-
ables identiﬁed after a thorough literature search. The vari-
ables were:
d Patient-related: age,11 sex,12 renal impairment,11 pul-
monary impairment,13 cardiac impairment,14 diabetes,
hypertension, malignancy,14 smoking, body mass in-
dex (BMI), anemia,15 and the American Society of An-
esthesiologists (ASA) Physical Status Classiﬁcation
score11;
d Aneurysm-related: maximum aneurysm diameter,11,16
aortic neck diameter, length, and angulation,11 and
iliac artery calciﬁcation; and
d Operation-related: anesthesia,17 adjuvant surgical pro-
cedures,18 and endograft generation.12
Subsequently, the variables with a P value of <.20 in
the univariable analysis and <15% missing data were
included in the Cox proportional hazards model (stepwise
backward method). The variables of the ERA model were
forced into the Cox proportional hazards model to identify
variables with additional value. The 2 log likelihood
(2LL) was reported to represent Cox model perfor-
mance. A lower 2LL represents better ﬁt of a multivari-
able model. The difference between Cox models was
tested with use of the 2LL in a c2 distribution.
Third, a sensitivity analysis was done to explore the in-
ﬂuence of the use of different endograft generations (early
vs late) on the outcomes. The sensitivity analysis included
AUC assessment per endograft generation and two multi-
variable Cox proportional hazard models to assess the asso-
ciation between endograft generation and reinterventions.
The ﬁrst Cox model used the end point reintervention,
including conversion, and the variables infrarenal neck
angulation, diameter, and length were included to adjust
for aortic anatomy-related confounding. In the second
Cox model, the outcomes reintervention and dying were
combined to a composite end point to prevent bias from
a competing risk of dying before a reintervention. The vari-
ables age, sex, previous history of malignancy, ASA 3 or 4,
year of intervention, AAA diameter, and infernal neckangulation, diameter, and length were included to adjust
for survival- and anatomy-related confounding.
Missing values. Of the 434 patients studied, ASA
scores were missing in 40 (9%) and were imputed with
ASA score 3, and serum creatinine levels were missing in
three (1%) and were imputed with the mean serum creati-
nine of the cohort. The preoperative CTA was available in
80% (349 of 434) of the patients. In the patients without a
CTA, the aneurysm diameter was collected from the med-
ical records. In these patients, the infrarenal neck length,
diameter, and angulation were missing, and the predictions
of reinterventions and endoleaks were excluded from the
analysis. Therefore, the predictions of the survival-related
outcomes were validated in 433 patients and of the rein-
terventions and endoleaks in 349 patients. An imputation
procedure for the missing data was considered but not
done because of the amount of missing data.
Ethics Committee approval. This study was conduct-
ed in accordance with the principles of the Declaration of
Helsinki. The Medical Ethics Committee determined
approval was not required because of the observational
design.RESULTS
A total of 433 patients with an asymptomatic AAA
were treated with EVAR. The median follow-up time was
4.8 years (IQR, 2.9-5.0 years), 86 of 433 patients (20%)
did not reach 5-year follow-up, and eight (2%) were lost
to follow-up. Baseline characteristics are reported in
Table I. The early death rate was 1% (3 of 433; 95% con-
ﬁdence interval [CI], 0%-2%), the 5-year survival rate was
65% (95% CI, 61%-70%), the 5-year reintervention rate
was 18% (95% CI, 14%-22%), and the 5-year rate of type
I, II, or III endoleak was 25% (95% CI, 20%-29%;
Table II). The actual outcome rates in patients treated
before 2007 were comparable to the estimations by the
Kaplan-Meier survival analysis.
External validation. The AUC (representing the
discrimination of the predictions by the ERA model) was
0.64 (95% CI, 0.19-1.0) for early death, 0.66 (95% CI,
0.60-0.72) for 3-year survival, and 0.66 (95% CI, 0.61-
0.71) for 5-year survival (AUCs are shown in Fig 1). The
AUC of the predictions for initial reintervention was 0.55
(95% CI, 0.42-0.68) and for midterm reintervention was
0.60 (95% CI, 0.51-0.69). The AUC of the predictions for
initial type I endoleak was 0.61 (95% CI, 0.37-0.85) and
for midterm type I endoleak was 0.59 (95% CI, 0.43-0.75).
The AUC of the predictions for initial type II endoleak was
0.50 (95% CI, 0.41-0.59) and for midterm type II endo-
leak was 0.47 (95% CI, 0.36-0.58). The calibration plot of
3-year survival showed that the agreement between pre-
dicted and observed survival was accurate (Fig 2). The
calibration plot of 5-year survival showed an overestimation
of survival by the predictions. A predicted 5-year survival of
50%, of 66%, and of 80% corresponded with an observed 5-
year survival of 39% (95% CI, 28-51%), 57% (95% CI, 45%-
69%), and 68% (95% CI, 55%-78%), respectively.
Table II. Outcomes after endovascular aneurysm repair
(EVAR)
General cohort outcomes Median (IQR) or % (No.)
Follow-up time, years 4.8 (2.9-5.0)
Censored before 5-year follow-up 20 (86/433)
Lost to follow-up 2 (8/433)
ERA model outcomes % (No.) 95% CI
Early death 1 (3) 0-2
3-year survival KMa 80 (87) 76-83
3-year survival actualb 80 (81/401) 76-83
5-year survival KMa 65 (137) 61-70
5-year survival actualc 65 (107/309) 60-70
Initial reintervention 4 (19) 3-7
Midterm reintervention 13 (57) 10-17
5-year reintervention KMa 18 (69) 14-22
5-year reintervention actualc 21 (64/310) 17-25
Initial endoleak type I 2 (9) 1-4
Midterm endoleak type I 4 (17) 2-6
Initial endoleak type II 11 (48) 8-14
Midterm endoleak type II 7 (31) 5-10
5-year endoleak type I, II, or III KMa 25 (108) 20-29
5-year endoleak type I, II, or III actualc 23 (71/311) 19-28
5-year conversion to ORc 9 (28/314) 6-13
CI, Conﬁdence interval; ERA, EVAR Risk Assessment; IQR, interquartile
range; KM, Kaplan-Meier; OR, open repair.
aEstimated by Kaplan-Meier survival analysis.
bActual rate in patients treated before July 1, 2009.
cActual rate in patients treated before July 1, 2007.
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ysis identiﬁed sex, age, BMI, cardiac and cerebrovascular
comorbidity, previous history of malignancy, smoking,
ASA score, serum creatinine, anemia, aneurysm diameter,
length of the infrarenal neck, adjunctive or ancillary proce-
dure during the operation, and endograft generation as
possible predictors of death (P < .20; Supplementary
Tables I and II, online only). Smoking, BMI, and length
of the infrarenal neck were not included in the Cox pro-
portional hazards model because of >15% missing data.
Age and serum creatinine were dichotomized because of
nonlinearity. Age, sex, cardiac comorbidity, previous his-
tory of malignancy, ASA score, serum creatinine, and
aneurysm diameter were identiﬁed as independent pre-
dictors of survival (P # .05; Table III). The 2LL of the
Cox model that included only the ERA variables was 1491.
The 2LL of the Cox model that included the ERA var-
iables, cardiac comorbidity, and previous history of malig-
nancy was 1476 (2LL difference 12, c2 with two with
degrees of freedom, P < .01).
Sensitivity analysis. From 2003 onward, more pa-
tients were treated with a late-generation endograft than
with an early-generation endograft. The median follow-up
time was 4.2 years (IQR, 1.5-5.0 years) for patients with an
early-generation endograft and 3.8 years (2.0-5.0 years) for
those with a late-generation endograft (P ¼ .69). After
stratiﬁcation for endograft generation, the AUCs changed
minimally, but the CIs increased (data not shown). The 5-
year reintervention rate, including conversions, was 29%(95% CI, 21%-37%) in patients with an early-generation
endograft and 16% (95% CI, 10%-21%) in patients with a
late-generation endograft (P < .01). After adjustment for
aortic anatomy-related confounders, the risk of reinter-
vention or conversion was lower in patients treated with a
late-generation endograft (adjusted hazard ratio, 0.49; 95%
CI, 0.29-0.84; Supplementary Table III, online only).
After adjustment for survival-related and aortic anatomy-
related confounders, the risk of reintervention or dying
was lower in patients with a late-generation endograft than
in patients with an early-generation endograft (adjusted
hazard ratio, 0.58; 95% CI, 0.39-0.86; Supplementary
Table IV, online only).
DISCUSSION
The present validation study shows that the predictions
by the ERA model of survival, reinterventions, and endo-
leaks after EVAR were not accurate in our cohort of Dutch
patients. The study was conducted as a ﬁrst step toward
prospective validation to determine long-term outcomes
after treatment allocation with support of the ERA model.
In such a prospective validation study, the question can be
answered whether our arbitrary AUC cutoff value of 0.70 is
sufﬁciently accurate to support decision making. However,
because of our disappointing results, further studies assess-
ing the effect of the present ERA model appear to be futile.
Prediction of survival. Our results for survival-related
outcomes conﬂict with the conclusions of the previous
validation studies.4,6,7 An explanation might be the inclu-
sion of relatively healthier patients in our cohort. The
proportion of patients with an ASA score 3 or 4 was 60%,
compared with 65% to 80% in previous validation studies.
The mean preoperative serum creatinine level was
93 mmol/L compared with 106 to 118 mmol/L, respec-
tively. Other preoperative variables, such as age, sex, and
aortic anatomy did not differ substantially. Since the
United Kingdom EndoVascular Aneurysm Repair 2 trial,1
we have become less willing to intervene in high-risk pa-
tients. However, without data on rejection rates, this
explanation is based on reasoning only; moreover, a reliable
prediction model should take potentially healthier patients
into account.
Another possible explanation for the disappointing ac-
curacy of the ERA model is that the discriminative char-
acter of the currently included variables is limited. For
this reason, we tried to identify possible additional predic-
tive variables. The Cox proportional hazards model identi-
ﬁed “cardiac comorbidity” (SVS/ISCS score $1) and
“previous history of malignancy” as independent predictors
of survival in our cohort. Beside commonly known predic-
tors of survival, “previous history of malignancy” might be
important to consider for long-term survival after EVAR.
However, these results have to be interpreted with caution
because of limitations that we will discuss later. Future
studies should determine the deﬁnite role of the variable
“previous history of malignancy.”
For the outcome early death, two new predictions
models have been developed recently19,20 and have shown
Fig 2. Calibration plots of the predicted 3-year and 5-year
survival and the corresponding observed survival. Only patients
with an intervention before July 2009 (3-year survival) or July
2007 (5-year survival) were included to ensure sufﬁcient follow-up
time. The range bars indicate the 95% conﬁdence interval
(CI) and the diagonal dashed line corresponds with ideal
calibration.
Fig 1. The area under the curve (AUC) (representing discrimination) of the predictions of survival, reinterventions,
and endoleaks by the EVAR Risk Assessment (ERA) model in the original Australian audit cohort and in the validations
in the United Kingdom (UK), Australia, and The Netherlands. An AUC >0.70 was considered as sufﬁciently accurate
(indicated by the bold dashed line). EVAR, Endovascular aneurysm repair.
Table III. Multivariable Cox proportional hazards
model (stepwise backward method) for survival after
endovascular aneurysm repair (EVAR)a
Variable Hazard ratio 95% CI P
Age $79 years 1.60 1.11-2.30 .01
Male sex 0.55 0.33-0.92 .02
Cardiac comorbidity
(SVS/ISCS score $1)
1.47 1.01-2.15 .05
Previous history of malignancy 2.02 1.39-2.93 <.01
ASA 3 or 4 2.00 1.32-3.03 <.01
Creatinine >104 mmol/L 1.44 1.00-2.07 .05
Aneurysm diameter (per 5 mm) 1.12 1.04-1.21 <.01
ASA, American Society of Anesthesiologists; CI, conﬁdence interval; ISCS,
International Society for Cardiovascular Surgery; IQR, interquartile range;
SD, standard deviation; SVS, Society for Vascular Surgery.
aThe model included 420 patients and 133 events, 2 log likelihood
(LL), 1476.
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studies.21,22 Possibly, these two models have more addi-
tional value in our clinical practice than the ERA model.
For 3-year and 5-year survival, the ERA model is the
most accurate model currently available. The combined
interpretation of the AUCs of all validations done so far
might be interpreted as sufﬁciently accurate for 3-year sur-
vival (AUCs ranging in all validations between 0.66 and
0.74) and 5-year survival (AUCs in all validations ranging
between 0.66 and 0.80).Prediction of reinterventions and endoleaks. Our
results on prediction of reinterventions and endoleaks
correspond with the conclusions in the previous validation
studies.4,6,7 Combined interpretation of the AUCs of for
the reinterventions and endoleaks cannot be interpreted as
sufﬁciently accurate. A probable explanation is that the
ERA model is based on an audit conducted between 1999
and 2001, which is quite some time ago. Clinical practice
has changed since the audit, especially in diagnosis and
treatment of endoleaks. Moreover, the indication for a
reintervention varies between hospitals. Without stan-
dardized treatment protocols, any model aiming to predict
reinterventions has to overcome this variation.
Clinical practice has changed since the Australian audit
also with regard to types of endografts. This might be
another reason the predictions of reinterventions and
endoleaks were not accurate. Our cohort includes a large
number of patients with early-generation endografts. The
ERA model aims to predict outcomes after all types of
endografts. Our cohort includes seven different types of
JOURNAL OF VASCULAR SURGERY
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tivity analysis showed that the accuracy of the predictions
by the ERA model barely differed stratiﬁed for endograft
generation. In accordance with recent results,23 the reinter-
vention rate was higher in early-generation endografts than
in late-generation endografts. After adjustment for possible
confounders, the risk of dying or reintervention was lower
in patients treated with a late-generation endograft. These
results indicate that new-generation endografts have
improved outcomes.
The ERA model focuses on aortic neck characteristics
for the prediction of reinterventions and endoleaks. Next
to the Australian audit, the importance of the aortic neck
for reinterventions and endoleaks has been reported from
the European Collaborators on Stent-Graft Techniques for
Abdominal Aortic Aneurysm Repair (EUROSTAR) regis-
try24,25 and conﬁrmed in more recent studies.26,27 This
shows that anatomic characteristics associated with these
predictions of the ERA might still be valid. However, two
other models aiming to predict reinterventions also include
other anatomic characteristics of the aortic neck (calciﬁca-
tion), of the aneurysm (angulation, branch vessels, diameter,
tortuosity), and of the iliac arteries (angulation, calciﬁcation,
diameter, length, and tortuosity).28,29 Possibly, these two
models have more additional value in our clinical practice
than the ERA model.
The identiﬁcation of anatomic predictors of reinterven-
tions and endoleaks was not possible in our cohort because
of too few adverse events. This problem might be
addressed by combining the data sets of all validation
studies to the ERA model done so far for a “meta-regres-
sion.” The number of adverse events would be increased,
and a multivariable analysis might identify other indepen-
dent predictors of outcomes. To increase reproducibility
of the measurements of aortic anatomy, an automatically
generated central lumen line might be relevant.30 Current
methods of measurement, using sagittal and coronal recon-
struction in the CTA, might be too observer-dependent.
Limitations. Despite the high number of patients
included in our validation of the ERA model, a limitation
was the low event rate for the outcomes of early death
and initial type I endoleak. For this reason, the CIs are
wide surrounding the AUCs, and the point estimates
should be interpreted with caution. All previous validation
studies have this limitation, which might be addressed by
combining the data sets for a “meta-validation.”
The retrospective design resulted in missing data. The
amount of missing data for the validation of the ERA
model was 1% of serum creatinine, 9% of ASA scores, and
20% of CTAs. The reason for the large proportion of
missing CTAs was that in one hospital, only images on
sheets were available before 2006. Comparing patients
with and without a preoperative CTA showed that the 5-
year survival rate was 66% (95% CI, 60%-71%) vs 65%
(95% CI, 55%-75%; P ¼ .97), the 5-year reintervention
rate was 19% (95% CI, 14%-23%) vs 18% (95% CI, 9%-
26%; P ¼ .90), and the 5-year endoleak rate was 26%
(95% CI, 21%-31%) vs 19% (95% CI, 10%-27%; P ¼ .21),respectively. Because these outcomes are comparable, we
expect little effect of the missing CTAs on the conclusions.
The Cox proportional hazards models also suffered
from missing data. Possible confounding factors, such as
smoking, BMI, and the length of the infrarenal aortic
neck, had to be excluded from the Cox model identifying
additional predictors of survival after EVAR (Table III).
Another limitation of this model was that our literature
search for inclusion of variables might have failed to iden-
tify all predictors. For example, the use of medication or
a preoperative electrocardiogram15 might be of impor-
tance. A large group of patients (27%) had to be excluded
from the Cox models in the sensitivity analysis
(Supplementary Tables III and IV, online only). For these
reasons, we are reluctant to draw deﬁnite conclusions from
the results of the Cox models.
In patients in whom decision making is difﬁcult, risk-
assessment by a prediction model has the most additional
value. For example, EVAR can be more challenging in
patients with hostile aortic anatomy, and the risk of reinter-
ventions and endoleaks is higher. OR is a reasonable alter-
native in these patients, and risk-assessment with a
prediction model might support making the decision.
Our validation study was too small to assess the accuracy
of the ERA model in a subgroup of patients with hostile
anatomy; however, this should be an important consider-
ation in future studies developing or validating prediction
models.
The primary objective of a vascular surgeon with
EVAR is the prevention of rupture and aneurysm-related
death. A ﬁnal limitation of our study was that we could
not objectify this aim by the validation of the predictions
of aneurysm-related death. The ERA model predictions
of 3-year and 5-year survival only correspond to the
population-related survival after EVAR. From a patient’s
perspective, however, the cause of death is not important
and the population-related survival sufﬁces.
CONCLUSIONS
This study is the third and largest external validation of
the ERA model. The predictions of early death, 3-year sur-
vival, 5-year survival, reinterventions, and type I, II, and III
endoleaks were not sufﬁciently accurate to be used in our
clinical practice. A multicenter prospective study is under-
way in Australia that aims to improve the predictive accu-
racy of the ERA model. We hope the results of this study
will produce a model that can support decision making in
our clinical practice.
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Supplementary Table I (online only). Univariable analysis of categoric preoperative patient-related, aneurysm-related,
and operation-related characteristics on 5-year survival after endovascular aneurysm repair (EVAR)
Variable No. 5-year survival, % Pa Missing data, % (No.)
Sexb
Male 386 67 .17 0
Female 47 54
Pulmonary comorbidity
Yes 120 63 .36 7 (30/433)
No 283 66
Cardiac comorbidityb
Yes 246 60 .02 3 (13/433)
No 174 72
Diabetes
Yes 60 65 .88 2 (8/433)
No 365 65
Hypertension
Yes 157 66 .89 3 (13/433)
No 263 63
Cerebrovascular comorbidityb
Yes 57 61 .17 1 (4/433)
No 372 66
Hypercholesterolemia
Yes 169 64 .93 3 (15/433)
No 249 66
Previous history of malignancyb
Yes 101 52 <.01 0
No 332 69
Current smoking
Yes 155 59 .12 17 (74/433)
No 204 67
Use of statin
Yes 203 60 .12 12 (54/433)
No 176 70
Use of oral anticoagulantsc
Yes 262 64 .73 12 (54/433)
No 117 65
Anemiab
Yes 111 56 .01 2 (9/433)
No 313 69
ASA scoreb
1 10 100 <.01 0
2 162 78
3 243 57
4 18 46
Aneurysm characteristics
Thrombus or calciﬁcation in the infrarenal neck
Yes 202 67 .52 20 (87/433)
No 144 65
Iliac calciﬁcation
Moderate/severe 228 63 .51 21 (89/433)
None/mild 116 69
Operating characteristics
Anesthesia
General 353 66 .81 8 (36/433)
Locoregional 44 65
Graft generation
Early 163 60 .19 8 (34/433)
Late 236 68
Adjunctive or ancillary procedureb
Yes 86 56 .03 0
No 347 68
ASA, American Society of Anesthesiologists; ISCS, International Society for Cardiovascular Surgery; SVS, Society for Vascular Surgery.
aLog-rank test.
bIncluded in multivariable Cox proportional hazards model (Table III).
cPlatelet aggregation inhibitor or vitamin K antagonist.
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Supplementary Table II (online only). Univariable analysis of continuous preoperative patient-related, aneurysm-
related, and operation-related characteristics on 5-year survival after endovascular aneurysm repair (EVAR)
Patient characteristics Mean Hazard ratio Pa Missing data, % (No.)
Age,b years 73.9 1.05 <.01 0
BMI, kg/m2 26.1 0.92 <.01 15 (67/433)
Serum creatinine,b mmol/L 93 1.01 <.01 0
Aneurysm characteristics
Maximum aneurysm diameter,b mm 62 1.03 <.01 0
Length infrarenal neck, mm 33 0.99 .05 19 (83/433)
Diameter infrarenal neck, mm 24 1.02 .61 19 (83/433)
Maximum AP/lateral infrarenal neck angulation, 29 1.00 .87 19 (83/433)
Maximum AP/lateral aneurysm angulation,  43 1.00 .48 19 (83/433)
AP, Anteroposterior; BMI, body mass index.
aUnivariable Cox proportional hazards model.
bIncluded in multivariable Cox proportional hazards model (Table III).
Supplementary Table III (online only). Multivariable Cox regression model to assess the association between
endograft generation (early vs late) and reinterventions, including conversions to open repair (OR)a
Variable No. Hazard ratio 95% CI P
Infrarenal neck angulation >45 1.59 0.86-2.93 .14
Infrarenal neck diameter, mm
<22 71 0.82 0.35-1.91 .64
22-26 170 1.33 0.69-2.56 .39
>26 85 Reference
Infrarenal neck length, mm
<24 88 2.16 0.97-4.81 .06
24-43 160 1.53 0.72-3.26 .27
>43 78 Reference
Late-generation endograft 0.49 0.29-0.84 .01
CI, Conﬁdence interval.
aThe model included 326 patients and 55 events, e2 log likelihood (LL), 591.
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Supplementary Table IV (online only). Multivariable Cox regression model to assess the association between
endograft generation (early vs late) and a combined end point of death and reinterventions, including conversions to open
repair (OR)a
Variable No. Hazard ratio 95% CI P
Age, years
<69 86 Reference
69-79 157 0.99 0.63-1.54 .95
>79 73 1.36 0.80-2.30 .25
Female sex 1.16 0.68-2.00 .53
Previous history of malignancy 1.66 1.14-2.43 <.01
ASA 3 or 4 1.39 0.95-2.03 .09
AAA diameter, mm
<61 159 Reference
61-67 76 1.18 0.76-1.83 .46
>67 81 1.49 0.98-2.28 .06
Infrarenal neck angulation >45 1.10 0.72-1.69 .66
Infrarenal neck diameter, mm
<22 66 1.07 0.62-1.84 .81
22-26 167 1.34 0.87-2.06 .18
>26 83 Reference
Infrarenal neck length, mm
<24 86 2.03 1.22-3.37 <.01
24-43 153 1.40 0.87-2.25 .17
>43 77 Reference
Year of intervention
<2004 95 Reference
2004-2006 105 1.15 0.81-1.85 .58
>2006 126 0.97 0.62-1.54 .91
Late-generation endograft 0.58 0.39-0.86 <.01
AAA, abdominal aortic aneurysm; ASA, American Society of Anesthesiologists; CI, conﬁdence interval.
aThe model included 316 patients and 139 events, e2 log likelihood (LL), 1479.
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